We develop novel disease modifying drugs.
Our mission is a simple question we ask ourselves — can we slow down or stop neurodegeneration when treating chronic neurological diseases?
Enterprise Estonia have confirmed their support for an Applied Research Program to develop a small molecule Glial cell line – Derived Neurotrophic Factor (GDNF) mimetics, for the treatment of Parkinson’s Disease and other indications.
Our drug design technologies for innovative target mechanisms enable the synthesis and development of novel small-molecule drug candidates and validate the target biology towards their proposed indications. These include Parkinson’s Disease, spinal cord injury, Huntington’s disease, motor neuronal disease, multiple sclerosis, Alzheimer’s disease and pain.
GeneCode designed and develops improved molecules using antisense mechanism of action which targets viral genomes and transcripts. By disrupting the viral lifecycle GeneCode`s approach is delivering promising treatment options for Hepatitis C, HIV and Chikungunya virus.
Drug design technology
All proprietary methods for novel drug design technologies and drug candidates developed by GeneCode are aimed to function as disease modifyers and ultimately as cures, not as disease symptom treatments
Platform technology patents
Both the identification and optimization of small molecule methods towards growth factor receptors and the antisense technologies have been globally patented and serve GeneCode`s new Technological Platforms of drug design.
We partner with various internationally well-known leading scientists in areas of biomedicine, who have numerous credits to their scientific work.
patents / families